drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00451 | DB08907 | 542 | 1,344 | [
"DDInter1064",
"DDInter280"
] | Levothyroxine | Canagliflozin | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
542,
24,
1344
]
],
[
[
542,
24,
549
],
[
549,
1,
1344
]
],
[
[
542,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
542,
21,
28680
],
[
28680,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Levothyroxine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Levothyroxine (Compound) causes Rash (Side Effect)... |
DB00176 | DB00757 | 529 | 1,166 | [
"DDInter770",
"DDInter581"
] | Fluvoxamine | Dolasetron | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
529,
25,
1166
]
],
[
[
529,
6,
12523
],
[
12523,
45,
1166
]
],
[
[
529,
21,
28726
],
[
28726,
60,
1166
]
],
[
[
529,
24,
214
],
[
214,... | [
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Dolas... | Fluvoxamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dolasetron (Compound)
Fluvoxamine (Compound) causes Oliguria (Side Effect) and Oliguria (Side Effect) is caused by Dolasetron (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and F... |
DB00852 | DB01203 | 1,445 | 699 | [
"DDInter1545",
"DDInter1255"
] | Pseudoephedrine | Nadolol | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
1445,
24,
699
]
],
[
[
1445,
24,
887
],
[
887,
1,
699
]
],
[
[
1445,
6,
3576
],
[
3576,
45,
699
]
],
[
[
1445,
21,
28882
],
[
28882,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Nadolol (Compound)
Pseudoephedrine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Nadolol (Compound)
Pseudoephedrine (Compound) causes Body temperature increased (Side E... |
DB00158 | DB01101 | 356 | 60 | [
"DDInter771",
"DDInter285"
] | Folic acid | Capecitabine | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Major | 2 | [
[
[
356,
25,
60
]
],
[
[
356,
21,
28701
],
[
28701,
60,
60
]
],
[
[
356,
24,
157
],
[
157,
24,
60
]
],
[
[
356,
24,
651
],
[
651,
63... | [
[
[
"Folic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capecitabine"
]
],
[
[
"Folic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (... | Folic acid (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Capecitabine (Compound)
Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Capecit... |
DB00647 | DB00983 | 675 | 480 | [
"DDInter528",
"DDInter776"
] | Dextropropoxyphene | Formoterol | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
675,
24,
480
]
],
[
[
675,
24,
1148
],
[
1148,
63,
480
]
],
[
[
675,
6,
6017
],
[
6017,
45,
480
]
],
[
[
675,
21,
28792
],
[
28792,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenalin... | Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Dextropropoxyphene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Formoterol (Compound... |
DB00262 | DB01208 | 552 | 945 | [
"DDInter302",
"DDInter1705"
] | Carmustine | Sparfloxacin | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Minor | 0 | [
[
[
552,
23,
945
]
],
[
[
552,
23,
739
],
[
739,
1,
945
]
],
[
[
552,
62,
1176
],
[
1176,
1,
945
]
],
[
[
552,
21,
28787
],
[
28787,
... | [
[
[
"Carmustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Carmustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Carmustine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Co... |
DB01138 | DB01229 | 804 | 973 | [
"DDInter1726",
"DDInter1377"
] | Sulfinpyrazone | Paclitaxel | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
804,
24,
973
]
],
[
[
804,
24,
310
],
[
310,
63,
973
]
],
[
[
804,
6,
8374
],
[
8374,
45,
973
]
],
[
[
804,
7,
16703
],
[
16703,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Sulfinpyrazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Sulfinpy... |
DB00697 | DB01166 | 876 | 477 | [
"DDInter1821",
"DDInter379"
] | Tizanidine | Cilostazol | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
876,
24,
477
]
],
[
[
876,
6,
7950
],
[
7950,
45,
477
]
],
[
[
876,
21,
28919
],
[
28919,
60,
477
]
],
[
[
876,
23,
112
],
[
112,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Tizanidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Tizanidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cilostazol (Compound)
Tizanidine (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB00047 | DB00978 | 176 | 739 | [
"DDInter932",
"DDInter1084"
] | Insulin glargine | Lomefloxacin | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Major | 2 | [
[
[
176,
25,
739
]
],
[
[
176,
25,
945
],
[
945,
40,
739
]
],
[
[
176,
25,
1176
],
[
1176,
1,
739
]
],
[
[
176,
24,
1344
],
[
1344,
... | [
[
[
"Insulin glargine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Insulin glargine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxa... | Insulin glargine may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Insulin glargine may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound)
Insuli... |
DB04855 | DB08901 | 540 | 1,468 | [
"DDInter602",
"DDInter1492"
] | Dronedarone | Ponatinib | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
540,
24,
1468
]
],
[
[
540,
25,
478
],
[
478,
24,
1468
]
],
[
[
540,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
540,
21,
28883
],
[
28883,... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib"... | Dronedarone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Dronedarone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Dronedarone (Compound) causes Skin ... |
DB01203 | DB09132 | 699 | 492 | [
"DDInter1255",
"DDInter797"
] | Nadolol | Gadoteric acid | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA). It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). Gadoterate meglumine has one o... | Moderate | 1 | [
[
[
699,
24,
492
]
],
[
[
699,
40,
668
],
[
668,
24,
492
]
],
[
[
699,
40,
668
],
[
668,
40,
461
],
[
461,
24,
492
]
],
[
[
699,
5,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoteric acid"
]
],
[
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
],
[
"Levobunolol",
"{u} may cause a moderat... | Nadolol (Compound) resembles Levobunolol (Compound) and Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Nadolol (Compound) resembles Levobunolol (Compound) and Levobunolol (Compound) resembles Timolol (Compound) and Timolol may cause a moderate interaction that... |
DB01073 | DB01206 | 1,488 | 37 | [
"DDInter745",
"DDInter1086"
] | Fludarabine | Lomustine | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1488,
24,
37
]
],
[
[
1488,
5,
11555
],
[
11555,
44,
37
]
],
[
[
1488,
21,
28675
],
[
28675,
60,
37
]
],
[
[
1488,
62,
1176
],
[
1176,... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Fludarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disea... | Fludarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound)
Fludarabine (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Lomustine (Compound)
Fludarabine may cause a minor interaction that can limit clin... |
DB00382 | DB06176 | 62 | 1,342 | [
"DDInter1734",
"DDInter1616"
] | Tacrine | Romidepsin | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
62,
24,
1342
]
],
[
[
62,
24,
112
],
[
112,
23,
1342
]
],
[
[
62,
24,
485
],
[
485,
24,
1342
]
],
[
[
62,
24,
1616
],
[
1616,
63... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentami... |
DB00572 | DB00774 | 85 | 1,577 | [
"DDInter136",
"DDInter889"
] | Atropine | Hydroflumethiazide | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Minor | 0 | [
[
[
85,
23,
1577
]
],
[
[
85,
23,
359
],
[
359,
40,
1577
]
],
[
[
85,
62,
323
],
[
323,
40,
1577
]
],
[
[
85,
23,
504
],
[
504,
1,
... | [
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
],
... | Atropine may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Atropine may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resemb... |
DB00497 | DB00902 | 828 | 104 | [
"DDInter1366",
"DDInter1168"
] | Oxycodone | Methdilazine | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
828,
24,
104
]
],
[
[
828,
63,
13
],
[
13,
24,
104
]
],
[
[
828,
24,
820
],
[
820,
1,
104
]
],
[
[
828,
24,
537
],
[
537,
40,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine a... |
DB01611 | DB08938 | 1,487 | 1,384 | [
"DDInter893",
"DDInter1112"
] | Hydroxychloroquine | Magaldrate | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1487,
24,
1384
]
],
[
[
1487,
63,
556
],
[
556,
23,
1384
]
],
[
[
1487,
64,
1178
],
[
1178,
23,
1384
]
],
[
[
1487,
62,
88
],
[
88,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valproic ac... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Hydroxychloroquine may lead to a major life threatening interaction when taken with Trifluoperazine ... |
DB00675 | DB08868 | 888 | 1,011 | [
"DDInter1744",
"DDInter737"
] | Tamoxifen | Fingolimod | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
888,
25,
1011
]
],
[
[
888,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
888,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
888,
23,
1247
],
[
124... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimo... | Tamoxifen (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Tamoxifen (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Tamoxifen may cause a minor interaction that can limit clinical effects when tak... |
DB01182 | DB11901 | 371 | 913 | [
"DDInter1534",
"DDInter107"
] | Propafenone | Apalutamide | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
371,
24,
913
]
],
[
[
371,
62,
112
],
[
112,
23,
913
]
],
[
[
371,
40,
271
],
[
271,
23,
913
]
],
[
[
371,
63,
600
],
[
600,
24,... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Propafenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Propafenone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Propafenone (Compound) resembles Mirabegron (Compound) and Mirabegron may cause a minor interaction that can... |
DB00163 | DB09036 | 1,461 | 812 | [
"DDInter1943",
"DDInter1668"
] | Vitamin E | Siltuximab | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Minor | 0 | [
[
[
1461,
23,
812
]
],
[
[
1461,
24,
792
],
[
792,
24,
812
]
],
[
[
1461,
23,
259
],
[
259,
24,
812
]
],
[
[
1461,
23,
270
],
[
270,
... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Siltuximab"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept and Rilonace... |
DB00026 | DB00381 | 1,184 | 376 | [
"DDInter94",
"DDInter79"
] | Anakinra | Amlodipine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Moderate | 1 | [
[
[
1184,
24,
376
]
],
[
[
1184,
24,
1428
],
[
1428,
1,
376
]
],
[
[
1184,
24,
1081
],
[
1081,
40,
376
]
],
[
[
1184,
24,
1101
],
[
1101,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Amlodipine (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Amlodipine (Compound)
An... |
DB00073 | DB11248 | 1,394 | 1,193 | [
"DDInter1608",
"DDInter1965"
] | Rituximab | Zinc gluconate | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
1394,
23,
1193
]
],
[
[
1394,
25,
725
],
[
725,
62,
1193
]
],
[
[
1394,
24,
1531
],
[
1531,
23,
1193
]
],
[
[
1394,
24,
270
],
[
270,
... | [
[
[
"Rituximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satraliz... | Rituximab may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may ... |
DB00991 | DB01166 | 97 | 477 | [
"DDInter1358",
"DDInter379"
] | Oxaprozin | Cilostazol | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
97,
24,
477
]
],
[
[
97,
21,
29340
],
[
29340,
60,
477
]
],
[
[
97,
75,
126
],
[
126,
23,
477
]
],
[
[
97,
24,
936
],
[
936,
63,... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Oxaprozin",
"{u} (Compound) causes {v} (Side Effect)",
"Stevens-Johnson syndrome"
],
[
"Stevens-Johnson syndrome",
... | Oxaprozin (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Cilostazol (Compound)
Oxaprozin (Compound) resembles Warfarin (Compound) and Oxaprozin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor inter... |
DB09046 | DB09118 | 1,094 | 1,580 | [
"DDInter1201",
"DDInter1711"
] | Metreleptin | Stiripentol | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1094,
24,
1580
]
],
[
[
1094,
24,
466
],
[
466,
62,
1580
]
],
[
[
1094,
62,
168
],
[
168,
24,
1580
]
],
[
[
1094,
63,
473
],
[
473,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Metreleptin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bor... |
DB00694 | DB01242 | 51 | 1,237 | [
"DDInter485",
"DDInter410"
] | Daunorubicin | Clomipramine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
51,
24,
1237
]
],
[
[
51,
64,
684
],
[
684,
1,
1237
]
],
[
[
51,
24,
1164
],
[
1164,
1,
1237
]
],
[
[
51,
63,
508
],
[
508,
1,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Th... | Daunorubicin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)... |
DB00719 | DB11859 | 1,219 | 418 | [
"DDInter149",
"DDInter230"
] | Azatadine | Brexanolone | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
1219,
24,
418
]
],
[
[
1219,
24,
100
],
[
100,
24,
418
]
],
[
[
1219,
63,
85
],
[
85,
24,
418
]
],
[
[
1219,
40,
830
],
[
830,
2... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and... |
DB00705 | DB11979 | 441 | 1,320 | [
"DDInter496",
"DDInter625"
] | Delavirdine | Elagolix | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
441,
25,
1320
]
],
[
[
441,
63,
168
],
[
168,
23,
1320
]
],
[
[
441,
25,
1297
],
[
1297,
24,
1320
]
],
[
[
441,
24,
26
],
[
26,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib... | Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Delavirdine may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may caus... |
DB00691 | DB01069 | 1,058 | 401 | [
"DDInter1237",
"DDInter1533"
] | Moexipril | Promethazine | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1058,
24,
401
]
],
[
[
1058,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1058,
24,
104
],
[
104,
24,
401
]
],
[
[
1058,
23,
460
],
[
460,
... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazi... |
DB00264 | DB08895 | 88 | 976 | [
"DDInter1200",
"DDInter1825"
] | Metoprolol | Tofacitinib | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
88,
24,
976
]
],
[
[
88,
24,
407
],
[
407,
63,
976
]
],
[
[
88,
24,
475
],
[
475,
24,
976
]
],
[
[
88,
23,
1479
],
[
1479,
24,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may caus... |
DB00047 | DB00795 | 176 | 50 | [
"DDInter932",
"DDInter1725"
] | Insulin glargine | Sulfasalazine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Moderate | 1 | [
[
[
176,
24,
50
]
],
[
[
176,
24,
161
],
[
161,
1,
50
]
],
[
[
176,
63,
305
],
[
305,
24,
50
]
],
[
[
176,
24,
590
],
[
590,
24,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Esc... |
DB00477 | DB11110 | 216 | 603 | [
"DDInter363",
"DDInter1115"
] | Chlorpromazine | Magnesium citrate | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
216,
24,
603
]
],
[
[
216,
25,
57
],
[
57,
24,
603
]
],
[
[
216,
40,
9
],
[
9,
24,
603
]
],
[
[
216,
24,
1616
],
[
1616,
24,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
... | Chlorpromazine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Chlorpromazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moder... |
DB00279 | DB01242 | 1,152 | 1,237 | [
"DDInter1074",
"DDInter410"
] | Liothyronine | Clomipramine | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1152,
24,
1237
]
],
[
[
1152,
24,
1164
],
[
1164,
1,
1237
]
],
[
[
1152,
6,
1829
],
[
1829,
45,
1237
]
],
[
[
1152,
21,
28882
],
[
288... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Liothyronine (Compound) binds ALB (Gene) and ALB (Gene) is bound by Clomipramine (Compound)
Liothyronine (Compound) causes Body temperature increased (S... |
DB06636 | DB11760 | 1,623 | 119 | [
"DDInter980",
"DDInter1742"
] | Isavuconazonium | Talazoparib | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1623,
24,
119
]
],
[
[
1623,
24,
985
],
[
985,
24,
119
]
],
[
[
1623,
25,
1670
],
[
1670,
24,
119
]
],
[
[
1623,
25,
1406
],
[
1406,
... | [
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
... | Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Isavuconazonium may lead to a major life threatening interaction when taken with Eliglustat and Eliglust... |
DB00981 | DB00985 | 1,528 | 1,443 | [
"DDInter1463",
"DDInter562"
] | Physostigmine (ophthalmic) | Dimenhydrinate | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Moderate | 1 | [
[
[
1528,
24,
1443
]
],
[
[
1528,
24,
1376
],
[
1376,
63,
1443
]
],
[
[
1528,
63,
357
],
[
357,
1,
1443
]
],
[
[
1528,
24,
358
],
[
358,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with D... |
DB00570 | DB00609 | 147 | 595 | [
"DDInter1936",
"DDInter694"
] | Vinblastine | Ethionamide | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Moderate | 1 | [
[
[
147,
24,
595
]
],
[
[
147,
18,
6584
],
[
6584,
57,
595
]
],
[
[
147,
21,
28709
],
[
28709,
60,
595
]
],
[
[
147,
24,
372
],
[
372,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Vinblastine",
"{u} (Compound) downregulates {v} (Gene)",
"SUZ12"
],
[
"SUZ12",
"{u} (Gene) is downregulated by... | Vinblastine (Compound) downregulates SUZ12 (Gene) and SUZ12 (Gene) is downregulated by Ethionamide (Compound)
Vinblastine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Ethionamide (Compound)
Vinblastine may cause a moderate interaction that could exacerbate disease... |
DB00279 | DB11124 | 1,152 | 209 | [
"DDInter1074",
"DDInter1560"
] | Liothyronine | Racepinephrine | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Racepinephrine is a racemic mixture consisting of d- and l- enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingred... | Moderate | 1 | [
[
[
1152,
24,
209
]
],
[
[
1152,
24,
22
],
[
22,
24,
209
]
],
[
[
1152,
1,
542
],
[
542,
24,
209
]
],
[
[
1152,
63,
73
],
[
73,
24,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine
Liothyronine (Compound) resembles Levothyroxine (Compound) and Levothyroxine may cause a moderate interactio... |
DB00584 | DB01246 | 610 | 820 | [
"DDInter638",
"DDInter45"
] | Enalapril | Alimemazine | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
610,
24,
820
]
],
[
[
610,
24,
104
],
[
104,
40,
820
]
],
[
[
610,
24,
401
],
[
401,
24,
820
]
],
[
[
610,
6,
8374
],
[
8374,
45... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB09263 | DB09407 | 1,436 | 853 | [
"DDInter1399",
"DDInter1114"
] | Patiromer | Magnesium chloride | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
1436,
24,
853
]
],
[
[
1436,
63,
544
],
[
544,
24,
853
]
],
[
[
1436,
25,
460
],
[
460,
63,
853
]
],
[
[
1436,
64,
286
],
[
286,
... | [
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
... | Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Patiromer may lead to a major life threatening interaction when taken with Magnesium carbon... |
DB00295 | DB04953 | 475 | 495 | [
"DDInter1244",
"DDInter708"
] | Morphine | Ezogabine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
475,
24,
495
]
],
[
[
475,
6,
15705
],
[
15705,
45,
495
]
],
[
[
475,
21,
28997
],
[
28997,
60,
495
]
],
[
[
475,
24,
1494
],
[
1494,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Ezogabine (Compound)
Morphine (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Ezogabine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Palon... |
DB00861 | DB06810 | 914 | 397 | [
"DDInter551",
"DDInter1484"
] | Diflunisal | Plicamycin | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
914,
24,
397
]
],
[
[
914,
24,
885
],
[
885,
24,
397
]
],
[
[
914,
63,
1061
],
[
1061,
24,
397
]
],
[
[
914,
24,
738
],
[
738,
6... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and ... |
DB00295 | DB01362 | 475 | 497 | [
"DDInter1244",
"DDInter960"
] | Morphine | Iohexol | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
475,
25,
497
]
],
[
[
475,
21,
29750
],
[
29750,
60,
497
]
],
[
[
475,
24,
323
],
[
323,
24,
497
]
],
[
[
475,
63,
88
],
[
88,
2... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Injection site pain"
],
[
"Injection site pain",
"{u} (Side Effect) is caused... | Morphine (Compound) causes Injection site pain (Side Effect) and Injection site pain (Side Effect) is caused by Iohexol (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause a moderate interaction that could exacerbate d... |
DB00321 | DB01218 | 21 | 1,493 | [
"DDInter78",
"DDInter852"
] | Amitriptyline | Halofantrine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
21,
25,
1493
]
],
[
[
21,
6,
3486
],
[
3486,
45,
1493
]
],
[
[
21,
21,
28809
],
[
28809,
60,
1493
]
],
[
[
21,
23,
112
],
[
112,
... | [
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Amitriptyline (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Halofantrine (Compound)
Amitriptyline (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Halofantrine (Compound)
Amitriptyline may cause a minor interaction that can limit clinical effects when taken with Metronid... |
DB00570 | DB00794 | 147 | 759 | [
"DDInter1936",
"DDInter1521"
] | Vinblastine | Primidone | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
147,
24,
759
]
],
[
[
147,
24,
697
],
[
697,
40,
759
]
],
[
[
147,
63,
362
],
[
362,
1,
759
]
],
[
[
147,
24,
157
],
[
157,
1,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compou... |
DB00189 | DB00434 | 459 | 13 | [
"DDInter691",
"DDInter459"
] | Ethchlorvynol | Cyproheptadine | Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
459,
24,
13
]
],
[
[
459,
24,
506
],
[
506,
63,
13
]
],
[
[
459,
24,
128
],
[
128,
24,
13
]
],
[
[
459,
25,
475
],
[
475,
24,
... | [
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"... | Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00060 | DB00476 | 912 | 109 | [
"DDInter947",
"DDInter608"
] | Interferon beta-1a | Duloxetine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
912,
24,
109
]
],
[
[
912,
24,
847
],
[
847,
1,
109
]
],
[
[
912,
24,
1387
],
[
1387,
63,
109
]
],
[
[
912,
63,
305
],
[
305,
24... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Duloxetine (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Terbinafine and Terbinafine may cause a moderate in... |
DB00705 | DB00877 | 441 | 629 | [
"DDInter496",
"DDInter1678"
] | Delavirdine | Sirolimus | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
441,
25,
629
]
],
[
[
441,
6,
21998
],
[
21998,
45,
629
]
],
[
[
441,
21,
29203
],
[
29203,
60,
629
]
],
[
[
441,
63,
1215
],
[
1215,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (Compoun... | Delavirdine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Sirolimus (Compound)
Delavirdine (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Delavirdine may cause a moderate inter... |
DB00692 | DB01018 | 274 | 1,364 | [
"DDInter1448",
"DDInter847"
] | Phentolamine | Guanfacine | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Moderate | 1 | [
[
[
274,
24,
1364
]
],
[
[
274,
10,
11590
],
[
11590,
44,
1364
]
],
[
[
274,
6,
10811
],
[
10811,
45,
1364
]
],
[
[
274,
21,
29118
],
[
29... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Phentolamine",
"{u} (Compound) palliates {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is... | Phentolamine (Compound) palliates hypertension (Disease) and hypertension (Disease) is treated by Guanfacine (Compound)
Phentolamine (Compound) binds NISCH (Gene) and NISCH (Gene) is bound by Guanfacine (Compound)
Phentolamine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Guanfa... |
DB00924 | DB01156 | 1,405 | 593 | [
"DDInter454",
"DDInter252"
] | Cyclobenzaprine | Bupropion | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
1405,
25,
593
]
],
[
[
1405,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1405,
21,
28757
],
[
28757,
60,
593
]
],
[
[
1405,
24,
1532
],
[
1532... | [
[
[
"Cyclobenzaprine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Cyclobenzaprine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Cyclobenzaprine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfa... |
DB00945 | DB08875 | 1,479 | 1,618 | [
"DDInter20",
"DDInter262"
] | Acetylsalicylic acid | Cabozantinib | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1479,
25,
1618
]
],
[
[
1479,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
1479,
63,
122
],
[
122,
24,
1618
]
],
[
[
1479,
62,
353
],
[
353,
... | [
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases w... |
DB00544 | DB01041 | 970 | 770 | [
"DDInter757",
"DDInter1789"
] | Fluorouracil | Thalidomide | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
970,
25,
770
]
],
[
[
970,
6,
7950
],
[
7950,
45,
770
]
],
[
[
970,
18,
11146
],
[
11146,
57,
770
]
],
[
[
970,
21,
29425
],
[
29425,
... | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Fluorouracil",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Th... | Fluorouracil (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound)
Fluorouracil (Compound) downregulates AMIGO2 (Gene) and AMIGO2 (Gene) is downregulated by Thalidomide (Compound)
Fluorouracil (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is ca... |
DB00095 | DB05239 | 66 | 866 | [
"DDInter623",
"DDInter425"
] | Efalizumab | Cobimetinib | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
66,
24,
866
]
],
[
[
66,
24,
482
],
[
482,
24,
866
]
],
[
[
66,
24,
496
],
[
496,
63,
866
]
],
[
[
66,
63,
58
],
[
58,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine ... |
DB00983 | DB01193 | 480 | 819 | [
"DDInter776",
"DDInter12"
] | Formoterol | Acebutolol | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
480,
24,
819
]
],
[
[
480,
64,
887
],
[
887,
1,
819
]
],
[
[
480,
63,
1121
],
[
1121,
1,
819
]
],
[
[
480,
6,
3576
],
[
3576,
45... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Formoterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
],
[
"Pindolol",
... | Formoterol may lead to a major life threatening interaction when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol (Compound) resembles Acebutolol (Compound)
Formoterol (Compoun... |
DB00562 | DB00938 | 1,014 | 455 | [
"DDInter188",
"DDInter1635"
] | Benzthiazide | Salmeterol | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1014,
24,
455
]
],
[
[
1014,
24,
688
],
[
688,
63,
455
]
],
[
[
1014,
24,
167
],
[
167,
23,
455
]
],
[
[
1014,
63,
251
],
[
251,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone an... |
DB01176 | DB09076 | 537 | 1,116 | [
"DDInter453",
"DDInter1899"
] | Cyclizine | Umeclidinium | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
537,
24,
1116
]
],
[
[
537,
24,
849
],
[
849,
24,
1116
]
],
[
[
537,
63,
1300
],
[
1300,
24,
1116
]
],
[
[
537,
74,
1408
],
[
1408,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Halop... |
DB00366 | DB00424 | 1,594 | 19 | [
"DDInter600",
"DDInter896"
] | Doxylamine | Hyoscyamine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Moderate | 1 | [
[
[
1594,
24,
19
]
],
[
[
1594,
24,
85
],
[
85,
63,
19
]
],
[
[
1594,
6,
7992
],
[
7992,
45,
19
]
],
[
[
1594,
21,
29093
],
[
29093,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Doxylamine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Hyoscyamine (Compound)
Doxylamine (Compound) ... |
DB00992 | DB08912 | 842 | 1,040 | [
"DDInter1182",
"DDInter462"
] | Methyl aminolevulinate (topical) | Dabrafenib | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
842,
24,
1040
]
],
[
[
842,
21,
29999
],
[
29999,
60,
1040
]
],
[
[
842,
63,
1101
],
[
1101,
23,
1040
]
],
[
[
842,
24,
868
],
[
868,
... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Methyl aminolevulinate",
"{u} (Compound) causes {v} (Side Effect)",
"Squamous cell carcinoma"
],
[
"Squamo... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Methyl aminolevulinate (Compound) causes Squamous cell carcinoma (Side Effect) and Squamous cell carcinoma (Side Effect) is caused by Dabrafenib (Compound)
Methyl aminolevulinate may cause a moderate intera... |
DB00443 | DB09020 | 251 | 28 | [
"DDInter195",
"DDInter212"
] | Betamethasone | Bisacodyl | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
251,
24,
28
]
],
[
[
251,
18,
20113
],
[
20113,
46,
28
]
],
[
[
251,
7,
3724
],
[
3724,
46,
28
]
],
[
[
251,
6,
1899
],
[
1899,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Betamethasone",
"{u} (Compound) downregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is upregulated by {... | Betamethasone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Bisacodyl (Compound)
Betamethasone (Compound) upregulates CDK5R1 (Gene) and CDK5R1 (Gene) is upregulated by Bisacodyl (Compound)
Betamethasone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Bisacodyl (Compound)
Betame... |
DB00047 | DB00741 | 176 | 167 | [
"DDInter932",
"DDInter885"
] | Insulin glargine | Hydrocortisone | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
176,
24,
167
]
],
[
[
176,
24,
1220
],
[
1220,
40,
167
]
],
[
[
176,
24,
870
],
[
870,
1,
167
]
],
[
[
176,
24,
1561
],
[
1561,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethaso... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) ... |
DB01309 | DB13928 | 1,254 | 1,385 | [
"DDInter933",
"DDInter1660"
] | Insulin glulisine | Semaglutide | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1254,
24,
1385
]
],
[
[
1254,
62,
1103
],
[
1103,
23,
1385
]
],
[
[
1254,
24,
1154
],
[
1154,
24,
1385
]
],
[
[
1254,
24,
1399
],
[
13... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Insulin glulisine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
... | Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Pasireotid... |
DB00305 | DB00363 | 377 | 695 | [
"DDInter1232",
"DDInter419"
] | Mitomycin | Clozapine | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Major | 2 | [
[
[
377,
25,
695
]
],
[
[
377,
6,
4973
],
[
4973,
45,
695
]
],
[
[
377,
18,
2976
],
[
2976,
57,
695
]
],
[
[
377,
24,
1001
],
[
1001,
... | [
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
]
],
[
[
"Mitomycin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clozapine"
... | Mitomycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clozapine (Compound)
Mitomycin (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Clozapine (Compound)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamin... |
DB00476 | DB00889 | 109 | 1,133 | [
"DDInter608",
"DDInter840"
] | Duloxetine | Granisetron | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Major | 2 | [
[
[
109,
25,
1133
]
],
[
[
109,
6,
12523
],
[
12523,
45,
1133
]
],
[
[
109,
21,
28851
],
[
28851,
60,
1133
]
],
[
[
109,
24,
1213
],
[
121... | [
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Granis... | Duloxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Granisetron (Compound)
Duloxetine (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Granisetron (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases whe... |
DB01089 | DB06691 | 1,340 | 849 | [
"DDInter502",
"DDInter1155"
] | Deserpidine | Mepyramine | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1340,
24,
849
]
],
[
[
1340,
63,
1648
],
[
1648,
24,
849
]
],
[
[
1340,
1,
1245
],
[
1245,
24,
849
]
],
[
[
1340,
24,
1053
],
[
1053,
... | [
[
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[... | Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Deserpidine (Compound) resembles Reserpine (Compound) and Reserpine may cause a moderate interaction that cou... |
DB00065 | DB09331 | 581 | 745 | [
"DDInter923",
"DDInter478"
] | Infliximab | Daratumumab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Major | 2 | [
[
[
581,
25,
745
]
],
[
[
581,
25,
139
],
[
139,
24,
745
]
],
[
[
581,
24,
597
],
[
597,
24,
745
]
],
[
[
581,
25,
287
],
[
287,
63,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} ... | Infliximab may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol... |
DB00414 | DB03754 | 590 | 1,400 | [
"DDInter16",
"DDInter1883"
] | Acetohexamide | Tromethamine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th e... | Minor | 0 | [
[
[
590,
23,
1400
]
],
[
[
590,
24,
1529
],
[
1529,
24,
1400
]
],
[
[
590,
24,
972
],
[
972,
63,
1400
]
],
[
[
590,
24,
1529
],
[
1529,
... | [
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tromethamine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Tromethamine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Choline... |
DB00313 | DB01069 | 556 | 401 | [
"DDInter1913",
"DDInter1533"
] | Valproic acid | Promethazine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
556,
24,
401
]
],
[
[
556,
24,
1264
],
[
1264,
63,
401
]
],
[
[
556,
24,
104
],
[
104,
24,
401
]
],
[
[
556,
6,
7603
],
[
7603,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Me... |
DB00264 | DB09038 | 88 | 1,450 | [
"DDInter1200",
"DDInter636"
] | Metoprolol | Empagliflozin | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
88,
24,
1450
]
],
[
[
88,
24,
659
],
[
659,
63,
1450
]
],
[
[
88,
24,
1061
],
[
1061,
24,
1450
]
],
[
[
88,
63,
1179
],
[
1179,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and T... |
DB00557 | DB09488 | 252 | 103 | [
"DDInter895",
"DDInter23"
] | Hydroxyzine | Acrivastine | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
252,
24,
103
]
],
[
[
252,
23,
771
],
[
771,
62,
103
]
],
[
[
252,
24,
85
],
[
85,
24,
103
]
],
[
[
252,
40,
1630
],
[
1630,
24,... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
... | Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atr... |
DB09046 | DB09330 | 1,094 | 985 | [
"DDInter1201",
"DDInter1352"
] | Metreleptin | Osimertinib | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1094,
24,
985
]
],
[
[
1094,
62,
168
],
[
168,
23,
985
]
],
[
[
1094,
63,
1478
],
[
1478,
24,
985
]
],
[
[
1094,
24,
1598
],
[
1598,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Metreleptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Metreleptin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacafto... |
DB00222 | DB09128 | 245 | 1,241 | [
"DDInter825",
"DDInter231"
] | Glimepiride | Brexpiprazole | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
245,
24,
1241
]
],
[
[
245,
24,
549
],
[
549,
24,
1241
]
],
[
[
245,
24,
1296
],
[
1296,
63,
1241
]
],
[
[
245,
63,
1179
],
[
1179,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin de... |
DB00279 | DB01193 | 1,152 | 819 | [
"DDInter1074",
"DDInter12"
] | Liothyronine | Acebutolol | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Minor | 0 | [
[
[
1152,
23,
819
]
],
[
[
1152,
23,
887
],
[
887,
1,
819
]
],
[
[
1152,
62,
88
],
[
88,
1,
819
]
],
[
[
1152,
6,
4973
],
[
4973,
45... | [
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pindolol"
],
[
... | Liothyronine may cause a minor interaction that can limit clinical effects when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Liothyronine may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol (Compound) resembles Acebutolol (Compound)
Liot... |
DB06603 | DB09065 | 39 | 760 | [
"DDInter1387",
"DDInter424"
] | Panobinostat | Cobicistat | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
39,
25,
760
]
],
[
[
39,
62,
479
],
[
479,
23,
760
]
],
[
[
39,
24,
1627
],
[
1627,
23,
760
]
],
[
[
39,
64,
1230
],
[
1230,
23,... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil... | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabi... |
DB00010 | DB00731 | 1,649 | 1,144 | [
"DDInter1661",
"DDInter1269"
] | Sermorelin | Nateglinide | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
1649,
24,
1144
]
],
[
[
1649,
24,
1021
],
[
1021,
63,
1144
]
],
[
[
1649,
24,
245
],
[
245,
24,
1144
]
],
[
[
1649,
24,
1021
],
[
1021... | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
... | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Gl... |
DB00377 | DB00539 | 1,494 | 11 | [
"DDInter1382",
"DDInter1837"
] | Palonosetron | Toremifene | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Major | 2 | [
[
[
1494,
25,
11
]
],
[
[
1494,
6,
7950
],
[
7950,
45,
11
]
],
[
[
1494,
21,
28646
],
[
28646,
60,
11
]
],
[
[
1494,
23,
1247
],
[
1247,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tor... | Palonosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Toremifene (Compound)
Palonosetron (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Toremifene (Compound)
Palonosetron may cau... |
DB01072 | DB05015 | 915 | 1,077 | [
"DDInter129",
"DDInter174"
] | Atazanavir | Belinostat | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Moderate | 1 | [
[
[
915,
24,
1077
]
],
[
[
915,
25,
1476
],
[
1476,
63,
1077
]
],
[
[
915,
24,
913
],
[
913,
63,
1077
]
],
[
[
915,
25,
478
],
[
478,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib... | Atazanavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may caus... |
DB00881 | DB01246 | 954 | 820 | [
"DDInter1554",
"DDInter45"
] | Quinapril | Alimemazine | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
954,
24,
820
]
],
[
[
954,
24,
104
],
[
104,
40,
820
]
],
[
[
954,
24,
401
],
[
401,
24,
820
]
],
[
[
954,
40,
675
],
[
675,
25,... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB08881 | DB11967 | 868 | 710 | [
"DDInter1925",
"DDInter210"
] | Vemurafenib | Binimetinib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
868,
24,
710
]
],
[
[
868,
63,
441
],
[
441,
24,
710
]
],
[
[
868,
25,
1293
],
[
1293,
24,
710
]
],
[
[
868,
64,
1593
],
[
1593,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
],
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Vemurafenib may lead to a major life threatening interaction when taken with Valbenazine and Valbenazine may... |
DB00641 | DB01072 | 467 | 915 | [
"DDInter1675",
"DDInter129"
] | Simvastatin | Atazanavir | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Major | 2 | [
[
[
467,
25,
915
]
],
[
[
467,
25,
1327
],
[
1327,
1,
915
]
],
[
[
467,
6,
4973
],
[
4973,
45,
915
]
],
[
[
467,
21,
29052
],
[
29052,
... | [
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u}... | Simvastatin may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Simvastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Simvastatin (Compound) causes Sleep disorder (Side Effect) and Sleep disorder (Si... |
DB00333 | DB00468 | 576 | 1,424 | [
"DDInter1166",
"DDInter1557"
] | Methadone | Quinine | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Major | 2 | [
[
[
576,
25,
1424
]
],
[
[
576,
6,
21998
],
[
21998,
45,
1424
]
],
[
[
576,
21,
29316
],
[
29316,
60,
1424
]
],
[
[
576,
40,
307
],
[
307,... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (Compound)",
... | Methadone (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Quinine (Compound)
Methadone (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Quinine (Compound)
Methadone (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that c... |
DB00705 | DB08899 | 441 | 129 | [
"DDInter496",
"DDInter649"
] | Delavirdine | Enzalutamide | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
441,
25,
129
]
],
[
[
441,
6,
8374
],
[
8374,
45,
129
]
],
[
[
441,
21,
28703
],
[
28703,
60,
129
]
],
[
[
441,
63,
608
],
[
608,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enz... | Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Delavirdine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and ... |
DB00262 | DB00987 | 552 | 1,224 | [
"DDInter302",
"DDInter460"
] | Carmustine | Cytarabine | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Moderate | 1 | [
[
[
552,
24,
1224
]
],
[
[
552,
5,
11555
],
[
11555,
44,
1224
]
],
[
[
552,
23,
872
],
[
872,
62,
1224
]
],
[
[
552,
23,
739
],
[
739,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Carmustine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Diseas... | Carmustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cytarabine (Compound)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken w... |
DB00390 | DB06410 | 1,252 | 1,196 | [
"DDInter554",
"DDInter595"
] | Digoxin | Doxercalciferol | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Moderate | 1 | [
[
[
1252,
24,
1196
]
],
[
[
1252,
23,
286
],
[
286,
63,
1196
]
],
[
[
1252,
24,
1017
],
[
1017,
63,
1196
]
],
[
[
1252,
1,
1482
],
[
1482,... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
... | Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Lorlat... |
DB00754 | DB01075 | 157 | 1,376 | [
"DDInter696",
"DDInter569"
] | Ethotoin | Diphenhydramine | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
157,
24,
1376
]
],
[
[
157,
24,
649
],
[
649,
63,
1376
]
],
[
[
157,
63,
128
],
[
128,
24,
1376
]
],
[
[
157,
24,
832
],
[
832,
... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine a... |
DB12332 | DB13179 | 1,619 | 68 | [
"DDInter1626",
"DDInter1882"
] | Rucaparib | Troleandomycin | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
1619,
24,
68
]
],
[
[
1619,
63,
1601
],
[
1601,
23,
68
]
],
[
[
1619,
62,
222
],
[
222,
23,
68
]
],
[
[
1619,
24,
466
],
[
466,
... | [
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loratadine"
],
[
... | Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Rucaparib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutra... |
DB00834 | DB04951 | 932 | 187 | [
"DDInter1215",
"DDInter1477"
] | Mifepristone | Pirfenidone | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
932,
24,
187
]
],
[
[
932,
63,
168
],
[
168,
23,
187
]
],
[
[
932,
25,
1670
],
[
1670,
63,
187
]
],
[
[
932,
24,
1017
],
[
1017,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Mifepristone may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cau... |
DB00673 | DB01125 | 723 | 279 | [
"DDInter112",
"DDInter98"
] | Aprepitant | Anisindione | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
723,
24,
279
]
],
[
[
723,
63,
467
],
[
467,
23,
279
]
],
[
[
723,
24,
918
],
[
918,
62,
279
]
],
[
[
723,
63,
175
],
[
175,
24,... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Anisindione
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bic... |
DB01122 | DB08865 | 158 | 1,593 | [
"DDInter61",
"DDInter448"
] | Ambenonium | Crizotinib | Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
158,
24,
1593
]
],
[
[
158,
63,
1528
],
[
1528,
24,
1593
]
],
[
[
158,
24,
617
],
[
617,
24,
1593
]
],
[
[
158,
24,
1011
],
[
1011,
... | [
[
[
"Ambenonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Ambenonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
],
[... | Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and ... |
DB00776 | DB01070 | 1,335 | 1,098 | [
"DDInter1360",
"DDInter558"
] | Oxcarbazepine | Dihydrotachysterol | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | A vitamin D that can be regarded as a reduction product of vitamin D2. | Moderate | 1 | [
[
[
1335,
24,
1098
]
],
[
[
1335,
63,
386
],
[
386,
25,
1098
]
],
[
[
1335,
24,
1041
],
[
1041,
25,
1098
]
],
[
[
1335,
40,
1236
],
[
1236... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalcifer... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Dihydrotachysterol
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol... |
DB00214 | DB00902 | 1,028 | 104 | [
"DDInter1836",
"DDInter1168"
] | Torasemide | Methdilazine | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1028,
24,
104
]
],
[
[
1028,
24,
820
],
[
820,
1,
104
]
],
[
[
1028,
24,
401
],
[
401,
63,
104
]
],
[
[
1028,
24,
286
],
[
286,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction th... |
DB00264 | DB09039 | 88 | 1,670 | [
"DDInter1200",
"DDInter629"
] | Metoprolol | Eliglustat | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
88,
24,
1670
]
],
[
[
88,
24,
478
],
[
478,
24,
1670
]
],
[
[
88,
23,
578
],
[
578,
24,
1670
]
],
[
[
88,
24,
1476
],
[
1476,
63... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor... |
DB01222 | DB04861 | 617 | 1,592 | [
"DDInter246",
"DDInter1271"
] | Budesonide | Nebivolol | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
617,
24,
1592
]
],
[
[
617,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
617,
63,
1479
],
[
1479,
23,
1592
]
],
[
[
617,
24,
578
],
[
578,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Budesonide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused ... | Budesonide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when tak... |
DB00209 | DB01085 | 352 | 562 | [
"DDInter1886",
"DDInter1465"
] | Trospium | Pilocarpine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist.[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine is used to treat dry mouth and various ophthalmic conditions, i... | Moderate | 1 | [
[
[
352,
24,
562
]
],
[
[
352,
6,
7992
],
[
7992,
45,
562
]
],
[
[
352,
21,
28847
],
[
28847,
60,
562
]
],
[
[
352,
24,
1507
],
[
1507,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pilocarpine"
]
],
[
[
"Trospium",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
... | Trospium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Pilocarpine (Compound)
Trospium (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Pilocarpine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dic... |
DB00880 | DB09268 | 359 | 1,662 | [
"DDInter360",
"DDInter1464"
] | Chlorothiazide | Picosulfuric acid | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
359,
24,
1662
]
],
[
[
359,
24,
708
],
[
708,
24,
1662
]
],
[
[
359,
63,
1573
],
[
1573,
24,
1662
]
],
[
[
359,
40,
504
],
[
504,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropi... | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00909 | DB01254 | 306 | 1,213 | [
"DDInter1971",
"DDInter484"
] | Zonisamide | Dasatinib | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
306,
24,
1213
]
],
[
[
306,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
306,
7,
5137
],
[
5137,
46,
1213
]
],
[
[
306,
18,
17480
],
[
17480,
... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Zonisamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Zonisamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Zonisamide (Compound) upregulates KDM5A (Gene) and KDM5A (Gene) is upregulated by Dasatinib (Compound)
Zonisamide (Compound) downregulates ENOPH1 (Gene) and ENOPH1 (Gene) is downregulated by Dasatinib (Compound)
Zonisamide (Com... |
DB08865 | DB15233 | 1,593 | 1,650 | [
"DDInter448",
"DDInter142"
] | Crizotinib | Avapritinib | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1593,
25,
1650
]
],
[
[
1593,
64,
1478
],
[
1478,
24,
1650
]
],
[
[
1593,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
1593,
24,
159
],
[
159... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} ma... | Crizotinib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a... |
DB00196 | DB11757 | 600 | 960 | [
"DDInter743",
"DDInter994"
] | Fluconazole | Istradefylline | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Moderate | 1 | [
[
[
600,
24,
960
]
],
[
[
600,
25,
1135
],
[
1135,
23,
960
]
],
[
[
600,
24,
77
],
[
77,
24,
960
]
],
[
[
600,
25,
866
],
[
866,
24,... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Nalox... | Fluconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may caus... |
DB00630 | DB11093 | 1,485 | 636 | [
"DDInter42",
"DDInter273"
] | Alendronic acid | Calcium citrate | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
1485,
24,
636
]
],
[
[
1485,
1,
1199
],
[
1199,
24,
636
]
],
[
[
1485,
24,
115
],
[
115,
25,
636
]
],
[
[
1485,
1,
1199
],
[
1199,
... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} ma... | Alendronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may lead t... |
DB00792 | DB09118 | 832 | 1,580 | [
"DDInter1878",
"DDInter1711"
] | Tripelennamine | Stiripentol | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
832,
24,
1580
]
],
[
[
832,
24,
1532
],
[
1532,
24,
1580
]
],
[
[
832,
24,
1609
],
[
1609,
63,
1580
]
],
[
[
832,
63,
128
],
[
128,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverin... |
DB00861 | DB01067 | 914 | 959 | [
"DDInter551",
"DDInter826"
] | Diflunisal | Glipizide | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
914,
24,
959
]
],
[
[
914,
63,
245
],
[
245,
40,
959
]
],
[
[
914,
24,
1411
],
[
1411,
1,
959
]
],
[
[
914,
18,
1918
],
[
1918,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB00543 | DB06663 | 87 | 1,154 | [
"DDInter82",
"DDInter1398"
] | Amoxapine | Pasireotide | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
87,
25,
1154
]
],
[
[
87,
63,
1314
],
[
1314,
40,
1154
]
],
[
[
87,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
87,
23,
112
],
[
112,
... | [
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopres... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Pasireotide (Compound)
Amoxapine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Amoxapine may cause a minor in... |
DB00427 | DB00761 | 1,233 | 1,621 | [
"DDInter1879",
"DDInter1497"
] | Triprolidine | Potassium chloride | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Major | 2 | [
[
[
1233,
25,
1621
]
],
[
[
1233,
63,
1105
],
[
1105,
25,
1621
]
],
[
[
1233,
24,
667
],
[
667,
64,
1621
]
],
[
[
1233,
24,
13
],
[
13,
... | [
[
[
"Triprolidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may lead to a major life threatening interaction when taken with Potassium chloride
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin an... |
DB00092 | DB06643 | 58 | 1,136 | [
"DDInter40",
"DDInter500"
] | Alefacept | Denosumab | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
58,
24,
1136
]
],
[
[
58,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
58,
24,
1316
],
[
1316,
63,
1136
]
],
[
[
58,
63,
1648
],
[
1648,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalumab ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.